IGF-Binding Protein 2 human,;, recombinant, expressed in (BTI-Tn-5B1-4) High-5 Insect Cells, >=98% (

Stock Code: 3593034
Manufacturer Part No: SRP3063-20UG

Order Now for 7 day delivery

Click Add to Quote for price and delivery

Quantity: - +

Descriptions

Application

IGF-Binding Protein 2 human has been used to study the vaccine-stimulated augmented immunity in the presence of IGFBP-2 in patients with metastatic breast cancer.

Biochem/physiol Actions

IGFBP-2 (insulin-like growth factor-binding protein 2) interacts with integrins and extracellular matrix via arginine-glycine-aspartic acid (RGD) and heparin-binding motifs. It participates in cell detachment, migration and invasion. IGFBP-2 is also associated with various malignancies, including ovarian cancer, breast cancer, colon cancer, lung cancer, prostate cancer, glioma and leukemia. It is suggested as a serum biomarker of Lupus Nephritis and is associated with the chronicity of renal pathology in patients. IGFBP-2 is upregulated in idiopathic pulmonary fibrosis.

General description

IGFBPs (insulin-like growth factor-binding proteins) are mainly required to regulate IGFs (insulin-like growth factors) activities. IGFBP-2 belongs to the IGFBP family of proteins. The protein has a IGF-binding site and a thyroglobulin type-1 domain. It interacts with IGF1 and IGF2. IGFBP-2 is widely expressed in tissues. This gene is mapped to human chromosome 2q35.Recombinant human IGF-BP2 is a 31.5kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Physical form

Lyophilized from 1x PBS, pH 7.2.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Sequence

EVLFRCPPCT PERLAACGPP PVAPPAAVAA VAGGARMPCA ELVREPGCGC CSVCARLEGE ACQVYTPRCG QGLRCYPHPG SELPLQALVM GEGTCEKRRD AEYGASPEQV ADNGDDHSEG GLVENHVDST MNMLGGGGSA GRKPLKSGMK ELAVFREKVT EQHRQMGKGG KHHLGLEEPK KLRPPPARTP CQQELDQVLE RISTMRLPDE RGPLEHLYSL HIPNCDKHGL YNLKQCKMSL NGQRGECWCV NPNTGKLIQG APTIRGDPEC HLFYNEQQEA RGVHTQRMQ